COPENHAGEN, Denmark — Latest results from the clinical trial program with BG-12 (dimethyl fumarate; Tecfidera, Biogen Idec) suggest sustained clinical efficacy and safety in patients with multiple ...
BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate). In ...
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial --240 mg of BG-12 Administered Either Twice or Three ...
WESTON, Mass., Apr 24, 2012 (BUSINESS WIRE) -- -- Regulatory Applications Submitted to the FDA and EMA -- Today Biogen Idec BIIB +2.11% announced that detailed positive data from CONFIRM, the second ...
CAMBRIDGE, Mass. – December 7, 2009 – Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) ...
BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results